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The main goal of chemotherapeutic drugs is to induce massive cell death in tumors. Cisplatin is an antitumor
drug widely used to treat several types of cancer. Despite its remarkable efficiency, most tumors show intrinsic or
acquired drug resistance. The primary biological target of cisplatin is genomic DNA, and it causes a plethora of
DNA lesions that block transcription and replication. These cisplatin-induced DNA lesions strongly induce cell
death if they are not properly repaired or processed. To counteract cisplatin-induced DNA damage, cells use an
intricate network of mechanisms, including DNA damage repair and translesion synthesis. In this review, we
describe how cisplatin-induced DNA lesions are repaired or tolerated by cells and focus on the pivotal role of
DNA repair and tolerance mechanisms in tumor resistance to cisplatin. In fact, several recent clinical findings
have correlated the tumor cell status of DNA repair/translesion synthesis with patient response to cisplatin
treatment. Furthermore, these mechanisms provide interesting targets for pharmacological modulation that
can increase the efficiency of cisplatin chemotherapy.
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’ INTRODUCTION
Nearly five decades after FDA (Food and Drug Administra-
tion) approval for the treatment of testicular cancer, cisplatin
remains one of the most effective antitumor agents. In fact,
in combination with bleomycin and etoposide, cisplatin
yields cure rates above 95% (1). In addition to its outstanding
success in testicular cancer, a wide variety of solid tumors,
such as ovarian, lung, bladder, cervical and head and neck
neoplasms, have also been shown to be highly responsive to
cisplatin (2). Nevertheless, there is consensus that tumor
resistance is the Achilles’ heel of cisplatin treatment.
Cisplatin is a small and remarkably simple molecule com-
posed of one platinum atom linked to two amides and two
chlorides; despite its size, it is a very powerful drug. In con-
ditions of low chloride concentration, as found in the cytosol,
cisplatin undergoes a process known as aquation, in which
one or two chlorides are replaced with water molecules
(Figure 1A). Through the aquation process, cisplatin becomes
highly reactive and readily binds to a variety of biomolecules
inside the cell (1). In its reactive form, cisplatin covalently
binds to DNA bases, forming DNA adducts. Cisplatin parti-
cularly reacts with the nucleophilic N7-sites of purine bases,
and a double reaction may covalently link purines. When
purines are located on the same strand, intrastrand adducts
are produced, or alternatively, an interstrand crosslink (ICL)
is generated if the purine are on opposite strands (3) (Figure 1B).
Cisplatin-induced DNA adducts block transcription and
DNA synthesis, which in turn triggers an intricate intracel-
lular signal transduction cascade in an orchestrated attempt
by the cells to eliminate the lesions. The cell cycle is arrested,
providing adequate time for DNA repair mechanisms to
remove the lesions. In cases of impaired repair or excessive
damage, the cells undergo apoptosis (3).
Although cisplatin is highly efficient, intrinsic resistance
and resistance acquired during treatment cycles are relatively
common and remain a major challenge for cisplatin-based
anticancer therapy. There are many ways in which cells block
cisplatin from reaching and damaging DNA, including
decreasing drug uptake, increasing drug efflux, and inducing
drug detoxification by covalent binding to glutathione or
metalloproteins (4-7) (Figure 2). However, once cisplatin reacts
with DNA, cells must remove or tolerate the lesions in
order to resist the treatment effects; otherwise, cisplatin-
induced DNA damage will induce massive cell death,
including by apoptosis.
Once cisplatin causes many different DNA lesions, most of
the major DNA repair systems are involved in removing
cisplatin-induced DNA damage. In fact, nucleotide excision
repair (NER), mismatch repair (MMR), homologous recom-
bination (HR) and nonhomologous end joining (NHEJ) are
involved in repairing cisplatin-induced DNA damage (8).
Alternatively, cisplatin-induced DNA damage can be toleratedDOI: 10.6061/clinics/2018/e478s
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by simply replicating the damaged molecule through a
system known as translesion synthesis (TLS) (9).
In this review, we describe how cisplatin-induced DNA
lesions are repaired or tolerated by human cells and discuss
the pivotal role of these mechanisms in tumor resistance to
cisplatin. Furthermore, we present the most recent clinical
findings correlating the DNA repair/TLS status of tumors
with the patient response to cisplatin treatment.
’ DNA REPAIR PATHWAYS
Nucleotide excision repair
The bulky DNA adducts generated by cisplatin are mainly
repaired by the NER pathway (Figure 3A). This repair mech-
anism is composed of two subpathways: global genome
repair (GGR), which recognizes and repairs damage through-
out the genome, and transcription-coupled repair (TCR),
which addresses lesions at actively transcribing genes.
Proteins in the NER pathway first recognize the lesion: this
step is accomplished by the heterodimer XPC-HR23B in
GGR and by the blockade of RNA polymerase II elonga-
tion, in association with the CSA and CSB proteins, in
TCR. The subsequent steps are shared by TCR and GGR
and involve double helix strand separation by specific
helicases (XPB and XPD, subunits of the TFIIH complex),
followed by cleavage of the damaged strand on both sides
of the lesion by the endonucleases XPF/ERCC1 and XPG,
which cleave the phosphodiester chain at the 5’ and
3’ ends, respectively, a few nucleotides away from the lesion.
Finally, the oligonucleotide (approximately 30 nucleotides
long) containing the lesion is excised, and the resulting gap is
filled in by DNA polymerase E using the intact strand as a
template (10).
Undoubtedly, cisplatin chemotherapy for testicular cancer,
including advanced metastatic testicular cancer, represents a
remarkable clinical success. The hypersensitivity of testicular
cancer cells to cisplatin reflects the clinical responses, so
many studies have been carried out in order to reveal the
molecular mechanisms that could possibly explain this
phenomenon (11). Data suggest that DNA repair deficiency
in testis cells is a determining factor for the high sensitivity of
this type of tumor to cisplatin. In fact, testis cell lines had a
lower capacity for repairing platinum-DNA adducts than cell
lines of bladder lineages, as observed either in the whole
genome or in actively transcribed genes (12). Subsequently,
the lower DNA repair capacity of testicular cancer cell lines
was confirmed by measuring the ability of cell extracts to
remove platinum-DNA adducts, and the addition of XPA
protein to the cell extracts was sufficient to restore in vitro
DNA repair capacity (12). Interestingly, XPA was not found
to be a rate-limiting protein for NER in UV-irradiated cells
(13), which was later also shown to be true for testicular
cancer cell lines treated with cisplatin, indicating that low
levels of XPA protein are not responsible for increased
sensitivity to cisplatin (13). More recently, testicular cancer
cell lines were shown to have normal repair of intrastrand
adducts and platinum-DNA adducts but reduced levels of ICL
repair compared to bladder cancer cell lines. In those studies,
Figure 1 - Cisplatin activation and DNA damage induction. A) The cisplatin activation process occurs by exchange of one or two of its
chlorides for water molecules (monoaquated and diaquated, respectively). B) Cisplatin can form covalent bonds with DNA. The major
DNA lesions are intrastrand DNA adducts and interstrand crosslinks (ICLs). The percentages represent the frequency of each type of
DNA damage induced by cisplatin.
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low levels of the ERCC1-XPF complex in testis cells cor-
relate well with low ICL repair, and this protein complex
seems to be the limiting factor for the repair of these lesions
and for cellular cisplatin resistance (14).
The fact that cisplatin has similar efficacy as first-line
therapy for other tumors strongly indicates that DNA repair
mechanisms play pivotal roles in drug resistance. In ovarian
cancer cell lines, early evidence indicated that cisplatin
resistance was mediated by a greater capacity to remove
cisplatin-induced DNA damage, including ICLs, and greater
tolerance of DNA damage (15,16). Later, it was shown that
ovarian tumors from treatment naïve patients had similar
levels of cisplatin-induced DNA damage, but tumor cells from
previously treated patients who showed resistance had an
enhanced capacity to remove cisplatin-induced ICLs (17).
Moreover, in a set of sensitive and acquired cisplatin-resistant
ovarian cell lines, resistance to cisplatin correlated with
resistance to UV light, which indicates a role for NER activity
in the drug resistance process (18).
Interestingly, the ERCC1/XPF complex seems to be asso-
ciated with cisplatin resistance in other tumors as well.
In fact, early data indicated that low expression of ERCC1 or
XPF was associated with increased sensitivity to cisplatin in
both cell lines and tumor tissues. In ovarian cancer cells,
ERCC1 expression was found to be induced after cisplatin
treatment (19), and this induction correlated with increased
capacity for the repair of cisplatin-induced DNA damage (20).
On the other hand, low ERCC1mRNA levels in primary gastric
adenocarcinoma and lung cancer showed a positive association
with improved survival of patients treated with cisplatin in
combination with fluorouracil or gemcitabine (21,22).
In addition to DNA adducts, which are the main sub-
strates for the NER pathway, ICL lesions are also generated
by cisplatin. There is abundant evidence that NER proteins
also play an important role in the ICL repair pathway.
Among NER proteins, XPD, XPF, XPG and ERCC1 partici-
pate in ICL repair. Thus, low levels of one of these genes
could, in principle, lead to even lower DNA repair capacity,
which in turn could induce more cell death. In agreement
with this hypothesis, XPD protein was shown to interact
with the HR protein Rad51 and increase the rate of ICL
removal (23).
Moreover, ERCC1 participates in both the NER and HR
pathways, increasing the importance of this protein for
DNA damage processing. In fact, ERCC1 deficiency leads to
higher sensitivity to cisplatin than does XPA deficiency (24).
In a study of 761 lung cancer patients, Olaussen et al. (25)
observed that almost half of them were negative for ERCC1
expression and that cisplatin treatment significantly pro-
longed the survival of patients with ERCC1-negative tumors
but not that of those with ERCC1-positive tumors. Similarly,
gastric adenocarcinoma patients with low ERCC1 levels
showed a greater benefit from cisplatin treatment than those
with high ERCC1 levels (21).
From the initial findings, consistent data indicate a good
correlation between the ERCC1/XPF nuclease, and NER
in general, and tumor resistance to cisplatin, although some
discrepant results of a lack of correlation have also been
reported (26). Thus, the use of ERCC1 (and/or other NER
genes) as predictors of tumor prognosis may be an impor-
tant clinical strategy. Moreover, recent data indicated that
ERCC1 silencing by RNA interference may provide a means
to potentiate cisplatin-induced tumor cell killing (27). These
data are not definitive and do not discount the rele-
vance of other DNA repair/tolerance pathways in cisplatin
resistance.
Figure 2 - Mechanisms of tumor cell resistance to cisplatin. Drug influx inside cells (i.e., decreased expression of transporter channels);
drug efflux outside cells (i.e., increased expression of multidrug transporter channels); drug detoxification (i.e., high levels of
glutathione or glutathione S-transferase); DNA repair capacity. Abbreviations: CTR1 (chloride transport receptor 1); GSH (glutathione);
GST (glutathione S-transferase); MRP-1 (multidrug resistance-associated protein 1); GS-X pump (ATP-dependent glutathione S-conjugate
export pump).
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Mismatch repair
The MMR pathway is the DNA repair mechanism res-
ponsible for correcting single-strand DNA (ssDNA) errors,
such as mismatches or insertions/deletions generated during
replication. Similar to NER, MMR consists of recognition,
excision, resynthesis and ligation of the newly synthetized
strand. The first step of the MMR pathway is accomplished
by two heterodimers, namely, the MutSa (formed by MSH2-
MSH6) and MutSb (MSH2-MSH3) heterodimers, which form
a complex with MutL. In a process regulated by ATP, this
complex slides up and down double-strand DNA until
it encounters proliferating cell nuclear antigen (PCNA) and
replication factor C (RFC), replication machinery proteins.
Then, the exonuclease EXO1 cleaves the DNA daughter
strand harboring nucleotide mismatches, and high-fidelity
replicative polymerases (Pold and PolE) fill the gap after
oligonucleotide excision. Finally, DNA ligase rejoins the
DNA sequence (28).
In addition to correcting postreplicative errors, MMR also
recognizes lesions caused by alkylating agents, including
cisplatin, that induce postreplicative mispairing, mainly involv-
ing G/T (Figure 3A). Nonetheless, the MMR pathway is
unable to repair these lesions because MMR replaces the
base opposite the cisplatin adduct, thus keeping the source
of the mismatch intact. Since it ultimately fails to fully
repair the lesion, the MMR pathway will start this process
again, leading to a so-called futile cycle. This constant
procedure of cutting and mending the DNA strand can
eventually lead to the formation of double-strand breaks
(DSBs) and the activation of DNA damage signaling factors,
including p53, ataxia telangiectasia mutated (ATM) and
ataxia telangiectasia related (ATR), ultimately triggering
apoptosis. In addition to the futile cycle, MMR proteins
may shield cisplatin adducts by inhibiting NER proteins
from repairing them, therefore allowing adducts to persist
and consequently enhancing cisplatin lethality (28). Thus,
contrary to deficiencies in NER, those in MMR mechan-
isms are thought to be involved in tumor resistance to
cisplatin, which has been corroborated by early studies
demonstrating that MMR deficiency confers resistance to
cisplatin in Escherichia coli (29).
Deficiency in the MMR pathway can occur either by epi-
genetic modification (gene silencing due to promoter methyl-
ation) or gene mutation (leading to protein dysfunction).
Figure 3 - Cisplatin-induced DNA lesions and repair mechanisms. A) The nucleotide excision repair (NER) pathway is responsible for
removing cisplatin-induced DNA adducts (such as 1,2 and 1,3 intrastrand adducts), while the mismatch repair (MMR) pathway can
recognize but not repair these adducts. B) Double-strand breaks are repaired by homologous recombination (HR) and nonhomologous
end joining (NHEJ). The NER, HR, translesion synthesis (TLS) and Fanconi anemia (FA) pathways are involved in ICL repair. C) Schematic
representation of lesion bypass of cisplatin-induced intrastrand crosslinks via the TLS pathway.
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The most common mechanism for MMR deficiency is CpG
island hypermethylation of the MLH1 promoter on both
alleles, and an alternative mechanism is genetic inheritance.
In the latter case, the MSH2, MLH1, PMS2 or MSH6 genes
are mutated, as seen in Lynch syndrome (30-32). In MMR-
deficient cells, mismatched nucleotides accumulate, generat-
ing microsatellite instability. Thus, impairment of this DNA
repair pathway is highly associated with several types of
cancer, including hereditary nonpolyposis colon cancer and
colorectal carcinoma. In addition, it is estimated that MMR
deficiencies are present in approximately 17% of all primary
tumors (33,34).
Promoter hypermethylation of MMR genes was shown
to actually increase after cisplatin treatment and, as a con-
sequence, contribute to the acquisition of resistance (35).
Accordingly, the cisplatin resistance of human ovarian or
colon cancer cell xenografts, which have hypermethylation of
the MLH1 gene promoter, grown in nude mice was over-
come when the cells were inoculated with the demethylating
agent 2’-deoxy-5-azacytidine (DAC) and the mice were
treated with cisplatin (36).
MMR deficiency has been implicated in many studies
as a relevant pathway for cisplatin resistance. For instance,
the loss of MLH1 in colon cancer cells resulted in a 2-fold
increase in cisplatin resistance (37). Similar results were
reported in the endometrial cancer cell line HEC59, which is
deficient in MSH2, in which a 1.8-fold increase in cisplatin
resistance was observed (38). In addition, genetic comple-
mentation of MLH1 in deficient cells restored cisplatin
sensitivity (39).
However, it is important to note that the changes
in cisplatin sensitivity in cell lines in culture are relatively
modest, and there are many conflicting reports regarding the
clinical impacts of MMR functional status on tumor cells and
patient survival. In an analysis of NSCLC (non-small
cell lung carcinoma) patients, Hsu et al. (40) showed that
hypermethylation of the promoter regions of the hMSH2 and
hMLH1 genes was associated with poor patient survival.
Similar results have been reported in ovarian and breast
cancer patients (41,42). On the other hand, Cooper et al. (43)
showed no correlation between MMR proficiency and
patient survival rate. Moreover, low levels of MSH2 were
correlated with the long-term survival of lung cancer
patients treated with cisplatin (44). Further studies are
therefore necessary to elucidate the role of MMR in cisplatin
resistance in cancer.
DSB and interstrand crosslink (ICL) repair
The HR and NHEJ pathways repair DNA DSBs, which can
be generated by the well-known agents ionizing radiation
and free radicals. In addition, the ICL repair process results
in DSBs, which are considered the most hazardous type of
DNA damage for a cell. This fact may be explained by the
difficulty in repairing this type of damage, since unlike all
other lesions that rely on an intact strand to serve as a
template for repair, the integrity of both DNA strands is lost
in DSBs (45).
In the event of a DSB, the HR mechanism uses a homo-
logous DNA sequence as a template to correct the broken
strand. Briefly, after DSB induction, a complex cascade of
reactions is triggered in order to arrest the cell cycle and
recruit DNA repair factors. The ATM kinase acts a DSB sensor
that leads to G1 arrest mediated by p53 phosphorylation.
Subsequently, ATR and DNA-PKcs (DNA-dependent pro-
tein kinase) are activated. ATR controls the response to
a large spectrum of DNA damage, including lesions that
interfere with DNA replication, such as ssDNA breaks (SSBs)
and stalled DNA replication forks, while ATM and DNA-
PKcs play an important role in responses to DSBs (46).
Finally, histone H2AX is phosphorylated at sites of DNA
lesions, enabling the recruitment of DNA repair proteins (47).
Since the HR pathway requires DNA strand homology
to repair DSBs, it generally works in only proliferating cells
after sister chromatids are synthetized in the S phase of the
cell cycle (48).
Contrary to error-free HR, the NHEJ pathway is consid-
ered an error-prone DNA repair mechanism because it may
delete some nucleotides during the ligation of DSBs (49).
In this pathway, DSBs are identified by Ku70/Ku80 hetero-
dimers. Then, DNA-PKcs binds to DNA, and the Artemis-
DNA-PKcs complex functions as an endonuclease, cleaving
several nucleotides at the DSB site. To complete the DNA
repair, resynthesis is accomplished by DNA polymerases m
and l, and DNA ligase IV restores the phosphodiester
backbone. Importantly, DSB repair in G0/G1 phase is
accomplished predominantly by NHEJ. In contrast, in order
to repair DSBs, HR requires a sister chromatid to serve as a
template to synthesize the portion of the strand undergoing
repair. Therefore, HR plays a major role in repairing lesions
in cells in S/G2 phase. This distinction has an obvious
impact on the selection of the repair strategy in proliferating
versus postmitotic cells (50).
ICLs are extremely cytotoxic, especially for proliferating
cells, because ICLs covalently bind the two strands of the
DNA helix together, which prevents strand separation and
thereby inhibits vital cellular processes such as DNA repli-
cation and transcription (51). Invariably, replication of DNA
containing ICLs induces DSBs, possibly due to collapse of the
replication fork. The repair of ICLs is incredibly complex and
involves numerous pathways, including NER, TLS, HR and
Fanconi anemia (FA) proteins (52) (Figure 3B). Briefly, the
XPF/ERCC1 nuclease complex cleaves one of the crosslinked
strands, generating an intrastrand dinucleotide adduct (53).
Subsequently, recombination proteins, including Rad51, Rad52,
XRCC2, XRCC3, and RPA, generate a structure called a
Holliday junction that is resolved by the MUS81/MMS4
complex (54). In addition to this pathway, the TLS process
performed by the error-prone DNA polymerase Z plays a
significant role in ICL repair (52,55). Furthermore, corro-
borating the fact that cells from FA patients are sensitive to
ICL-inducing agents, there is evidence indicating that the
FA/BRCA pathway participates in both ICL and DSB
repair by HR (56).
ICL repair in human cells is greatly dependent on the cell
cycle status, which means that the genetic requirements for
repair and the repair outcomes for these particular types of
lesions are quite different in dividing and nondividing cells.
In this section, however, assuming that malignant tumors
ultimately increase in size through uncontrolled proliferation
of abnormal cells, we have decided to focus exclusively on
insights from current investigations concerning the mech-
anism of ICL repair in dividing cells.
ICLs represent only o5% of total DNA platination.
Nevertheless, this type of DNA lesion is one of most deadly
induced by cisplatin because the information encoded by
the complementary strand cannot be accessed while DNA
strands remain crosslinked. The introduction of these lesions
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in DNA can lead, therefore, to impaired replication and
transcription and can hinder any other process requiring
strand separation, thereby triggering cell death. There is a
large amount of experimental evidence suggesting that in
mammalian cells, genomic ICLs are targeted by the so-called
FA/BRCA pathway, which might explain why FA patients
are particularly affected by alkylating agents at the cellular
level.
Normal replication or cell exposure to several ICL damag-
ing agents triggers a sequence of molecular events leading to
activation of the FA/BRCA pathway. The early event in FA
pathway activation is the formation of the FA core complex,
which monoubiquitinates the FANCD2 and FANCI proteins,
a crucial step in FA/BRCA pathway activation. The innate
recognition and early processing stages of ICL in dividing
cells seem to be mediated by two partially redundant
signaling pathways involving FA proteins, RPA, PCNA
and BRCA2, which encounter the lesion at the replication
fork and collapse it during S phase, as well as components of
the NER pathway, such as XPA and XPC-HR23B, at the G1
phase of the cell cycle. Therefore, ICL-induced replication
arrest during S phase activates the assembly of the FA core
complex, as well as the monoubiquitination of FANCD2/
FANCI, which is translocated to the chromatin, where it
binds other repair factors, such as BRCA1, g-H2AX, Rad51
and PCNA. Once a set of DNA damage recognition proteins
is established, the endonuclease complex ERCC1-XPF is
immediately recruited to the site of DNA damage, preparing
the next step of the repair process.
Downstream events of ICL repair require the coordinated
and hierarchical action of three classical pathways, namely,
the NER, TLS and HR pathways. Replication fork stalling is
also recognized by the FANCM–FAAP24–MHF complex,
which recruits the FA core and Bloom helicase complex to
chromatin and activates ATR/ATRIP signaling through the
binding of RPA to ssDNA. The first incision at the damaged
strand is accomplished by active Mus81-Eme1 endonuclease,
thus converting the stalled replication fork to a DSB. As already
mentioned, ICLs covalently link two bases on comple-
mentary strands of DNA; thus, after the first 3’ incision,
the lesion remains attached to both strands. However, after
the second 5’ incision, carried out by XPF-ERCC1, a stable
flap is formed, and the lesion is properly removed from the
lagging strand template, allowing a translesion polymer-
ase to extend the leading strand synthesis past the
removed lesion and thereby generating a double-stranded
structure appropriate for sustained targeted HR. In addi-
tion to HR, the NER system may also be involved in the
repair of the broken sister chromatid and the removal of
the adduct remaining attached to the parental strand.
Since abrogation of at least five interlinked pathways (FA,
NER, Bloom, ATR/ATRIP signaling and HR) renders cells
particularly vulnerable to ICL-inducing anticancer drugs,
it seems logical to suppose that the genes integrating these
pathways are potentially implicated in the outcome of cancer
treatment. Burkitt and Ljungman (57) reported the validation
of a clinical protocol for the prognosis and treatment opti-
mization of head and neck cancer cells by comparing the
functional status of the FA/BRCA pathway and cisplatin
sensitivity. As a result, recruitment of FANCD2 to nuclear
foci was significantly correlated with greater sensitivity to
cisplatin. Furthering this line of research, the same authors (58)
reported that the histone deacetylase inhibitor phenyl-
butyrate sensitizes human cells to cisplatin. Inhibition of
the FA/BRCA pathway through BRCA1 downregulation
seems to be responsible for the sensitization, since pre-
treatment with phenylbutyrate increased cisplatin sensi-
tivity in cisplatin-resistant head and neck cancer cells while
simultaneously decreasing cisplatin-induced FANCD2 foci
formation.
There has been a considerable increase in the body of
evidence showing a link between virtually all HR-related
proteins and the mechanism of either inherent or acquired
cellular resistance to cisplatin. The identification of the
MCM8-MCM9 complex, which promotes RAD51 recruit-
ment to damage sites in mammalian cells, thereby allow-
ing the high-throughput assessment of DNA repair through
HR, strongly supports this idea. Depletion of MCM8 or
MCM9 in human cancer cells or MCM9 loss of function in
mouse embryo fibroblasts sensitizes cells to ICL-inducing
agents, such as cisplatin (59).
’ CISPLATIN-INDUCED DNA DAMAGE TOLERANCE
Translesion synthesis
Cisplatin-induced intrastrand adducts are bulky lesions
that interfere with DNA replication machinery by arresting
replicative DNA polymerases. The prolonged stalling of
replication forks can result in the formation of DNA DSBs,
and such deleterious damage can lead to gross DNA rearrange-
ments or cell death (60). To avoid the collapse of arrested
replication forks, DNA damage can be tolerated by
TLS (61) (Figure 3C). TLS is performed by specialized
polymerases (TLS Pol) of the Y (Polymerase Z (PolZ), Poli,
Polk and Rev1) and B families (such as Polz) that have
a broad catalytic site and lack proofreading activity,
enabling it to bypass the lesion in an accurate or mutagenic
manner (62).
PolZ is responsible for the TLS of a number of bulky DNA
adducts, including UV-induced cyclobutane pyrimidine
dimers. In vitro studies have shown that human PolZ is
also able to replicate cisplatin-GG adducts (63) by inserting
a correct dCMP opposite the 3’dG of cisplatin-GG and con-
tinuing chain elongation; PolZ can also incorporate an
incorrect nucleotide, and in that case, it is not able to extend
the primer (64). Moreover, structural and biochemical analyses
have shown that PolZ inserts the correct nucleotide
opposite the first G of cisplatin-GG, but it is less efficient
and promiscuous in the bypass of the 5’dG (65,66). Human
cells lacking PolZ are more sensitive to cisplatin treatment
than wild-type cells or the same cell lines complemented
with functional PolZ, demonstrating the physiological
relevance of the ability to bypass cisplatin-induced intra-
strand adducts by PolZ (67). Importantly, although the
sensitivity of XP-V cells to cisplatin was comparable to
that of NER-deficient XP-A cells, PolZ was shown to be
essential for overcoming cisplatin-induced S phase arrest
and to colocalize with monoubiquitinated PCNA (67); this
posttranslational modification of the clamp occurs in the
early steps of TLS. Additionally, upon cisplatin treatment,
PolZ was strongly induced in a P53-dependent manner (68),
and it was necessary for the progression of replication
forks in human cells (69). These findings demonstrate the
role of PolZ in the TLS of cisplatin-induced intrastrand
adducts in the human genome.
Moreover, another TLS polymerase, Polz, which is formed
by at least two subunits, Rev3L and Rev7, is also involved
in the bypass of cisplatin-induced intrastrand adducts.
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Indeed, transformed mouse cells lacking Polz were shown to
be more sensitive to cisplatin than their Polz-proficient
counterparts (70). Additionally, knockdown of the catalytic
subunit of Polz, Rev3L, rendered human cells more sensitive
to the cytotoxic effects of cisplatin (71). In addition to PolZ
and Polz, TLS Pol Rev1 was also shown to be important for
the bypass of cisplatin-induced intrastrand adducts (72).
Despite its ability to insert one dCMP opposite the DNA
damage, Rev1 plays a noncatalytic role in TLS by scaffolding
TLS polymerases, such as Polz, to DNA (73).
A more recent study showed that the TLS of cisplatin-
induced bulky adducts is in fact dictated by a two-Pol
mechanism (74). By using plasmids carrying specific single-
site lesions and knocking down TLS polymerases, the authors
demonstrated that PolZ or Polk inserts the first nucleotides
in front of the cisplatin-GG, followed by extension of the
DNA primer by Polz. It is worth noting that PolZ activity
results in error-free translesion replication, while Polk in
combination with Polz results in error-prone TLS past
cisplatin adducts (74). In agreement, Wei Yang’s group was
the first to purify human Polz and demonstrated in vitro that
the bypass of cisplatin-GG requires PolZ to insert dCMP
opposite the 3’dG and Polz to extend the primers (75).
Because the tolerance of intrastrand crosslinks counteracts
cisplatin-induced cell death, TLS Pol expression has been
correlated with resistance to this drug. The analysis of sixty-
four mucosal-derived head and neck squamous cell carcino-
mas (HNSCCs) revealed that PolZ expression was elevated
in 67% of the samples and that low PolZ levels were signi-
ficantly associated with a high complete response rate after
cisplatin treatment (76). A recent report showed elevated
PolZ expression in ovarian cancer stem cells isolated from
ovarian cancer cell lines and primary tumors (77). In this
study, knockdown of PolZ blocked cancer stem cell enrich-
ment by enhancing cisplatin-induced apoptosis.
The data indicate that TLS mediated by PolZ is involved in
the survival of cancer stem cells upon cisplatin treatment,
and the authors propose targeting PolZ as a strategy to
increase the efficiency of this chemotherapeutic. Moreover,
Polz expression has also been reported as a predictor of
cisplatin resistance. The analysis of Rev3L expression revealed
higher protein levels in human glioma than in normal
brain tissues (78). The engineered overexpression of Rev3L
in a glioma cell line attenuated cisplatin-induced apopto-
sis, while depletion of this protein increased cell sensitivity
to this drug. Additionally, the analysis of 123 patients with
squamous cell cervical carcinoma who had adjuvant
chemoradiation therapy after radical surgery revealed that
Polz expression is a significant predictor of recurrence
and that positive Polz expression is associated with the
depth of cervical stromal invasion (79). In agreement, it
was recently reported that Polz expression is higher in
cervical cancer than in normal tissue; in cervical cancer, the
depletion of Rev3L increased cisplatin sensitivity, while
Rev3L overexpression conferred cisplatin resistance by
decreasing cisplatin-induced apoptosis (80). These authors
also propose targeting these TLS Pols to counteract cisplatin
resistance.
On the other hand, because TLS Pols can be error-prone
when they bypass intrastrand adducts, they can contribute to
the acquisition of cisplatin resistance. In human fibroblasts,
cisplatin induced Rev3L expression in a concentration- and
time-dependent manner, and Rev3L depletion decreased
HR and TLS, not intrastrand adduct repair, upon cisplatin
treatment (71). These data strongly indicate that in addition
to its role in cell survival upon cisplatin treatment, Polz is
involved in genetic instability and the subsequent generation
of drug-resistant variants in the surviving population (71).
In human colon carcinoma cell lines, Rev3L depletion
decreased mutagenicity and acquired resistance to cisplatin.
The enhanced cisplatin-induced mutagenicity observed in
cancer cells defective for MMR was completely dependent on
Polz (81). Therefore, Polz plays a central role in mutagenicity
and cisplatin resistance in cancer cells, particularly in MMR-
deficient cancer cells.
Rev1 was also shown to be involved in the acquisition
of cisplatin resistance. Overexpression of human Rev1 in
human ovarian carcinoma enhanced cisplatin-induced muta-
genicity and cisplatin resistance after sequential cycles of
drug exposure that mimic clinical schedules of drug
administration (82). In agreement, suppression of Rev1 in a
mouse model of B cell lymphoma inhibited cisplatin-induced
mutagenesis and acquired resistance upon repeated cycles of
tumor engraftment and treatment (83).
Therefore, inhibition of TLS polymerases can have a dual
anticancer effect, sensitizing the tumors to the drug and
limiting the emergence of tumor chemoresistance. Indeed,
Xie et al. (83) evaluated the effect of Rev3L depletion on the
response to cisplatin in vivo in aggressive late-stage lung
carcinoma; the tumors exhibited pronounced sensitivity to
the treatment, followed by a significant increase in the overall
survival of treated mice. Additionally, Rev3L-depleted cells
presented diminished mutagenesis, a process that is highly
correlated with the induction of secondary malignancies
following chemotherapy.
’ DNA REPAIR MODULATION STRATEGIES
DNA repair and DNA damage tolerance play crucial roles
in the response to cisplatin treatment, making DNA damage
response and repair proteins tempting therapeutic targets to
modulate chemoresistance, sensitize tumor cells to cisplatin
and enhance chemotherapeutic efficiency. However, many of
the agents developed so far have shown low target specifi-
city and have failed to reach the clinic.
Due to the success of PARP inhibitors in the treatment
of BRCA-deficient tumors, there has recently been renewed
interest in developing small molecule inhibitors of DNA
repair proteins (Table 1) (84). In NER, the main targets are the
Table 1 - Summary of DNA repair inhibitors used in combination
with cisplatin.
Pathway Target Compound Ref
F06/NERI02 (85)
ERCC1-XPF E-X PPI2 (87)
NER E-X AS7 (87)
ERCC1-XPA NERI02 (88)
RPA-DNA TDRL-551 (89)
RPA MCI13E (90)
MMR MLH1 FdCyd (91)
Decitabine (92)
DDR ATR VX-970 (93)
AZD6738 (94)
NHEJ DNA-PKcs NU7026 (95)
NU7441 (95)
HR Rad51-ssDNA B02 (96)
TLS PCNA T2AA (97)
Revl Compound 4/5 (98)
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RPA and XPA proteins and the ERCC1-XPF heterodimer.
An in silico screen identified a compound—F06/NERI02
(NSC130813)—that, despite its modest in vitro affinity for
XPF (30 mM), blocked the ERCC1-XPF interaction and
increased cisplatin sensitivity (85). Other in silico studies
identified several catechol and hydroxyl-imide/pyridine/
pyrimidinone agents as ERCC1-XPF inhibitors, such as E-X
PPI2 and E-X AS7. E-X PPI2 significantly reduced ERCC1-
XPF heterodimer levels in ovarian cancer cells, blocked NER
activity (IC50 = 20 mM) and enhanced melanoma cell
sensitivity to cisplatin. E-X AS7 displayed greater specificity
for inhibiting NER activity (IC50 = 2 mM) and increased the
cisplatin sensitivity of NER-proficient, not NER-deficient,
human cells (86,87). Another compound, NERI01, inhibited
the interaction between ERCC1 and XPA, sensitizing colon
cancer cells to UV irradiation, but had a weaker effect on
cisplatin sensitivity (88).
Another promising target is replication protein A (RPA),
which plays important roles in both the NER and HR path-
ways and is overexpressed in a number of tumors. RPA is a
ssDNA binding protein that supports NER-catalyzed repair
of bulky adduct DNA damage. The compound TDRL-551
showed a synergistic effect with cisplatin due to its ability to
block the RPA-DNA interaction (89). Another mechanism
of inhibition involving covalent modification of RPA was
discovered with the isoborneol haloacetate MCI13E, which
greatly potentiated the cisplatin-induced death of lung cancer
cells (90).
In contrast to deficiencies of other repair pathways,
deficiency of the MMR pathway improves damage tolerance,
contributing to increased mutagenicity, tumor heterogeneity
and chemoresistance. Therefore, there is no interest in
developing inhibitors of MMR proteins. Since MMR activity
increases cell sensitivity to cisplatin, the research focus has
been on compounds that restore MMR function. In many
cancers, the hMLH1 gene promoter is hypermethylated,
causing a reduction in MLH1 protein levels. Cell-based
studies have shown that a fluoropyrimidine derivative,
5-fluoro-2-deoxycytidine (FdCyd), and a cytidine analog,
2’-deoxy-5-azacytidine (decitabine), have potential utility in
reversing this hypermethylation, restoring MMR function-
ality and consequently sensitizing cells to cisplatin (91,92).
Due to the involvement of several different pathways
in the repair of ICLs, there are many proteins that can be
inhibited to induce sensitization to cisplatin. One of these
targets is the kinase ATR, which is involved in the DNA
damage response (DDR) signaling pathway and in the HR
pathway, for which there are two inhibitors in phase 1 and
2 trials (VX-970 and AZD6738, respectively). VX-970 inhibits
ATR (IC50 = 19 nM) and induces a 10-fold increase in the
sensitivity to cisplatin in half of the cell lines tested; it also
significantly improved the responses to cisplatin in xenograft
models derived from primary human NSCLC samples (93).
Accordingly, AZD6738, an orally active and bioavailable
inhibitor, showed strong synergy with cisplatin in lung
cancer cell lines (94).
DSBs are formed during the process of repairing ICLs, and
these highly toxic lesions can be repaired by either the HR
or NHEJ pathway. For the NHEJ pathway, there are two
highly selective DNA-PKcs inhibitors, NU7026 and NU7441,
that showed synergy with cisplatin in BRCA1-deficient
breast cancer cell lines (95). For the HR pathway, one of the
strategies involves inhibiting DNA strand exchange acti-
vity by disrupting the ability of Rad51 to bind ssDNA.
The compound B02 has such activity; it inhibits HR and
increases cancer sensitivity to several DNA damaging
agents, including cisplatin (96).
The TLS pathway is another important step in the
completion of ICL repair. The compound T2AA has been
demonstrated to enhance cisplatin cytotoxicity by inhibiting
the interaction between mono-ubiquitinated PCNA and
REV1, resulting in blockade of ICL repair (97). Two com-
pounds, named compound 4 and 5, that inhibit REV1,
thereby sensitizing human cancer cells to cisplatin and
decreasing cisplatin-mediated mutagenesis, were recently
developed. These compounds showed no activity in a Rev1-/-
MEF cell line, indicating that they are specific for Rev1 (98).
The clinical benefit of cisplatin as an antitumoral agent
is unquestionable. However, tumor resistance to cisplatin
remains a major challenge, and there is clearly an urgent
need to improve the therapeutic protocol. Certainly, cisplatin
binding to DNA causes the most damage, as this is the main
mechanism by which it induces cell death. Once DNA is
damaged, the cells must either repair or tolerate the lesions.
Thus, DNA repair and tolerance systems are imperative for
tumor cell survival and resistance to cisplatin. Therefore,
targeting the different DNA repair processes is a tempting
therapeutic strategy to enhance the anticancer effects of
cisplatin, hopefully with clinical benefits to patients and
improvements in their quality of life.
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